LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

LLY

988.57

+2.13%↑

JNJ

225.57

+0.63%↑

ABBV

206.03

-1.03%↓

UNH

363.82

-1.87%↓

AZN

181.33

-1.06%↓

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Uždarymo kaina

10 -6.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.93

Max

10.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.5M -29M
Darbuotojai	103
EBITDA	-2M -32M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+99.21% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.7B 3.2B
Ankstesnė atidarymo kaina	16.37
Ankstesnė uždarymo kaina	10

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-05 23:43; UTC

Svarbiausios naujienos

New Zealand's Unemployment Rate Falls in 1Q

2026-05-05 23:20; UTC

Karštos akcijos

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026-05-05 21:48; UTC

Uždarbis

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026-05-05 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026-05-06 00:00; UTC

Rinkos pokalbiai

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026-05-05 23:39; UTC

Rinkos pokalbiai

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026-05-05 22:26; UTC

Rinkos pokalbiai

AMD Data-Center Business Continues to Surge -- Market Talk

2026-05-05 22:20; UTC

Rinkos pokalbiai

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026-05-05 22:08; UTC

Uždarbis

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026-05-05 22:07; UTC

Uždarbis

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Rev $1.2B >PAAS

2026-05-05 21:42; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:38; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:30; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:29; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:26; UTC

Uždarbis

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q EPS 39c >ALC.EB

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026-05-05 21:24; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:18; UTC

Uždarbis

Mistras Backs 2026 Rev $730M-$750M >MG

2026-05-05 21:17; UTC

Uždarbis

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026-05-05 21:15; UTC

Uždarbis

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026-05-05 21:12; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026-05-05 21:11; UTC

Uždarbis

SSR Mining 1Q Rev $581.8M >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q EPS $1.16 >SSRM

2026-05-05 21:08; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:01; UTC

Uždarbis

Intact Financial 1Q EPS C$4.12 >IFC.T

2026-05-05 21:01; UTC

Karštos akcijos

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

99.21% į viršų

12 mėnesių prognozė

Vidutinis 20.2 USD 99.21%

Aukščiausias 30 USD

Žemiausias 9 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.